Busulfan

In some countries, this medicine may only be approved for veterinary use.

In the US, Busulfan (busulfan systemic) is a member of the drug class alkylating agents and is used to treat Bone Marrow Transplantation, Chronic Myelogenous Leukemia and Thrombocythemia.

US matches:

• Busulfan


• Busulfan Tablet


• Busulfan Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01AB01

CAS registry number (Chemical Abstracts Service)

0000055-98-1

Chemical Formula

C6-H14-O6-S2

Molecular Weight

246

Therapeutic Category

Antineoplastic agent, alkylating agent

Chemical Name

1,4-Butanediol, dimethanesulfonate

Foreign Names

• Busulfanum (Latin)
• Busulfan (German)
• Busulfan (French)
• Busulfano (Spanish)

Generic Names

• Busulfan (OS: BAN, DCF)
• Busulphan (OS: BAN)
• BUS (IS)
• CB 2041 (IS)
• GT 41 (IS)
• Myelosanum (IS: USSRP)
• Tetramethylendi(methansulfonat) (IS: IUPAC)
• Busulfan (PH: BP 2010, Ph. Eur. 6, Ph. Int. 4, USP 32, JP XV)
• Busulfanum (PH: Ph. Int. 4, Ph. Eur. 6)

Brand Names

• Busilvex
  PF, Luxembourg; Pierre Fabre, United Arab Emirates; Pierre Fabre, Austria; Pierre Fabre, Belgium; Pierre Fabre, Bahrain; Pierre Fabre, Czech Republic; Pierre Fabre, Germany; Pierre Fabre, Denmark; Pierre Fabre, Egypt; Pierre Fabre, Spain; Pierre Fabre, Finland; Pierre Fabre, United Kingdom; Pierre Fabre, Ireland; Pierre Fabre, Iraq; Pierre Fabre, Iran; Pierre Fabre, Italy; Pierre Fabre, Jordan; Pierre Fabre, Kuwait; Pierre Fabre, Lebanon; Pierre Fabre, Netherlands; Pierre Fabre, Norway; Pierre Fabre, Oman; Pierre Fabre, Qatar; Pierre Fabre, Saudi Arabia; Pierre Fabre, Sweden; Pierre Fabre, Syria; Pierre Fabre, Yemen; Pierre Fabre Médicament, France; Robapharm, Switzerland; Tema Medical, South Africa



• Busulfano Allen
  Allen, Spain



• Busulfano
  Bestpharma, Chile; IFET, Greece



• Busulfex
  Biem, Turkey; ESP Pharma, United States; ESP Pharma Kirin, Hong Kong; Orphan, Australia; Orphan, Israel; Otsuka, United States; PDL, United States



• Mablin
  Ohara Yakuhin, Japan



• Mylaren
  GlaxoSmithKline, Bangladesh



• Myleran
  Glaxo Wellcome, Portugal; GlaxoSmithKline, United Arab Emirates; GlaxoSmithKline, Argentina; GlaxoSmithKline, Austria; GlaxoSmithKline, Australia; GlaxoSmithKline, Belgium; GlaxoSmithKline, Bahrain; GlaxoSmithKline, Brazil; GlaxoSmithKline, Canada; GlaxoSmithKline, Chile; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Estonia; GlaxoSmithKline, Egypt; GlaxoSmithKline, Ethiopia; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Guyana; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Israel; GlaxoSmithKline, India; GlaxoSmithKline, Iraq; GlaxoSmithKline, Iran; GlaxoSmithKline, Iceland; GlaxoSmithKline, Italy; GlaxoSmithKline, Jordan; GlaxoSmithKline, Kuwait; GlaxoSmithKline, Lebanon; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Luxembourg; GlaxoSmithKline, Mexico; GlaxoSmithKline, Netherlands; GlaxoSmithKline, New Zealand; GlaxoSmithKline, Oman; GlaxoSmithKline, Poland; GlaxoSmithKline, Qatar; GlaxoSmithKline, Romania; GlaxoSmithKline, Russian Federation; GlaxoSmithKline, Saudi Arabia; GlaxoSmithKline, Sweden; GlaxoSmithKline, Singapore; GlaxoSmithKline, Slovenia; GlaxoSmithKline, Syria; GlaxoSmithKline, Thailand; GlaxoSmithKline, Turkey; GlaxoSmithKline, Taiwan; GlaxoSmithKline, United States; GlaxoSmithKline, Yemen; GlaxoSmithKline, South Africa; Wellcome, Ireland; Wellcome Foundation, Slovakia



• Myléran
  The Wellcome Foundation Limited, Tunisia



• Myleran (veterinary use)
  GlaxoSmithKline, United Kingdom

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.